Corpus Pharmaceuticals India Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 24-05-2024
- Paid Up Capital ₹ 0.10 M
as on 24-05-2024
- Company Age 6 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 99.58%
(FY 2020)
- Profit 96.84%
(FY 2020)
- Ebitda 96.95%
(FY 2020)
- Net Worth -3.91%
(FY 2020)
- Total Assets 242.05%
(FY 2020)
About Corpus Pharmaceuticals India
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Prashant and Vijender Singh serve as directors at the Company.
- CIN/LLPIN
U33100DL2018PTC339418
- Company No.
339418
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Sep 2018
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
South Delhi, Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Corpus Pharmaceuticals India?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Prashant  | Director | 25-Sep-2018 | Current |
| Vijender Singh | Director | 29-Jun-2021 | Current |
Financial Performance of Corpus Pharmaceuticals India.
Corpus Pharmaceuticals India Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 99.58% increase. The company also saw a substantial improvement in profitability, with a 96.84% increase in profit. The company's net worth dipped by a decrease of 3.91%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Corpus Pharmaceuticals India?
Unlock access to Corpus Pharmaceuticals India's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
- Astroveda Applications Private LimitedActive 3 years 4 months
Prashant and Vijender Singh are mutual person
- Corpus Retails Private LimitedActive 5 years 10 months
Prashant and Vijender Singh are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Corpus Pharmaceuticals India?
Unlock and access historical data on people associated with Corpus Pharmaceuticals India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Corpus Pharmaceuticals India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Corpus Pharmaceuticals India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
